AU8897698A - Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening - Google Patents

Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Info

Publication number
AU8897698A
AU8897698A AU88976/98A AU8897698A AU8897698A AU 8897698 A AU8897698 A AU 8897698A AU 88976/98 A AU88976/98 A AU 88976/98A AU 8897698 A AU8897698 A AU 8897698A AU 8897698 A AU8897698 A AU 8897698A
Authority
AU
Australia
Prior art keywords
viral drug
compositions
resistance
methods
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU88976/98A
Inventor
Daniel J. Capon
Neil T. Parkin
Jeannette M. Whitcomb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of AU8897698A publication Critical patent/AU8897698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU88976/98A 1997-07-30 1998-07-30 Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening Abandoned AU8897698A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90350797A 1997-07-30 1997-07-30
US08903507 1997-07-30
PCT/US1998/015967 WO1999006597A1 (en) 1997-07-30 1998-07-30 Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Publications (1)

Publication Number Publication Date
AU8897698A true AU8897698A (en) 1999-02-22

Family

ID=25417619

Family Applications (1)

Application Number Title Priority Date Filing Date
AU88976/98A Abandoned AU8897698A (en) 1997-07-30 1998-07-30 Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening

Country Status (6)

Country Link
EP (1) EP1012334A4 (en)
JP (1) JP2001512036A (en)
KR (1) KR20010022420A (en)
AU (1) AU8897698A (en)
CA (1) CA2298102A1 (en)
WO (1) WO1999006597A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
ATE447621T1 (en) * 1996-01-29 2009-11-15 Monogram Biosciences Inc METHOD FOR DETERMINING ANTIVIRAL ACTIVE SUBSTANCE SUSCEPTIBILITY AND RESISTANCE AND ANTIVIRAL ACTIVE SCREENING
US20030028011A1 (en) * 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
AU7268000A (en) * 1999-07-21 2001-02-13 Martin Heinkelein Method for quantization of the antiviral effect of antiviral active principles
AU785353B2 (en) * 2000-06-08 2007-02-01 Virco Bvba Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
DK1490383T3 (en) * 2002-03-11 2009-06-08 Lab 21 Ltd Method and composition for the identification and characterization of hepatitis C
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
EP2463389A1 (en) 2006-10-20 2012-06-13 Innogenetics N.V. Methodology for analysis of sequence variations within the HCV NS5B genomic region
WO2008046923A2 (en) 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
WO2013082617A1 (en) * 2011-12-02 2013-06-06 Laboratory Corporation Of America Holdings Methods for the phenotypic detection of hcv inhibitor resistant subpopulations
CN113299340B (en) * 2021-06-09 2023-06-30 四川大学华西医院 Screening method of target test drugs and target test drug screening device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291893A1 (en) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
EP0662128B1 (en) * 1992-09-28 2005-11-23 Chiron Corporation Methods and compositions for controlling translation of hcv proteins
AU1923795A (en) * 1994-02-18 1995-09-04 University Of Washington Methods and compositions for screening for anti-aids drugs
NZ325912A (en) * 1996-01-26 1999-01-28 Virco Nv Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains
ATE447621T1 (en) * 1996-01-29 2009-11-15 Monogram Biosciences Inc METHOD FOR DETERMINING ANTIVIRAL ACTIVE SUBSTANCE SUSCEPTIBILITY AND RESISTANCE AND ANTIVIRAL ACTIVE SCREENING

Also Published As

Publication number Publication date
KR20010022420A (en) 2001-03-15
EP1012334A4 (en) 2004-12-29
CA2298102A1 (en) 1999-02-11
EP1012334A1 (en) 2000-06-28
WO1999006597A1 (en) 1999-02-11
JP2001512036A (en) 2001-08-21

Similar Documents

Publication Publication Date Title
IL125464A0 (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
AU2661997A (en) Compositions and methods for screening drug libraries
HUP0004318A3 (en) Pharmaceutical composition comprising atorvastatin and an antihypertensive agent
HUP0103406A3 (en) 1h-imidazopyridine derivatives and pharmaceutical compositions thereof
AU7275098A (en) Enhanced adenovirus-assisted transfection composition and method
IL133613A0 (en) Epothilone derivatives and pharmaceutical compositions containing same
AU6886198A (en) Compositions and screening methods for neutrophil responses
HUP0102990A3 (en) Tetrahydroimidazo-naphtyridine derivatives and pharmaceutical compositions thereof
AU6269896A (en) Cellular apoptosis susceptibility protein (csp) and antisens e csp
HUP0103203A3 (en) Azaadamantane derivatives and pharmaceutical compositions thereof
AU8897698A (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
AU8494998A (en) Procedures and materials for conferring disease resistance in plants
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
AU7685798A (en) Compositions and methods for preventing adhesion
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
AU9301998A (en) Composition and methods using galectin-1
IL140742A0 (en) Raloxifene and pharmaceutical composition comprising the same
SG71754A1 (en) Copolymer and copolymer composition
EP0922211A4 (en) Dynamometer and calibration technique therefor
AU3486297A (en) Drug resistance and multidrug resistance modulators
EP0987942A4 (en) Pharmaceutical composition and methods for using it
GB9713666D0 (en) Biosensor materials and methods
AU7681498A (en) Pharmaceutical composition and use thereof
PL336004A1 (en) Anribacterial substituted 7-acylamino-3-(methylhydrazone) methylcephalosporins and their intermediate products
AU1664299A (en) Autodegradable microcarriers and their use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase